Clinical trials
Advanced Triple Negative Breast Cancer clinical trials
Below are recruiting advanced triple negative breast cancer clinical trials, each written for real people, not researchers. We’re tracking 197 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06532812RecruitingPhase 1/Phase 2
TIL therapy plus immunotherapy for advanced breast cancer
This trial tests a personalized therapy using your own immune cells (TILs) combined with immunotherapy to fight advanced breast cancer that has not responded to other treatments. It may help if you have a tumor that can be biopsied and you are generally healthy enough for the procedures.
Beijing, Beijing MunicipalityAges 16–90 - NCT07646106RecruitingPhase 1
Testing THE-0504 in Advanced Solid Tumors
This Phase 1 trial tests a new drug called THE-0504 in patients with advanced solid tumors (like lung, colon, pancreas, stomach, or breast cancer) that have not responded to standard treatments. The study aims to find the right dose and understand how well and safely the drug works.
Rome, LazioAges 18 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Odense CAges 18 years+ - NCT07623369RecruitingPhase 1
First-in-Human Study of HH160 for Advanced Solid Tumors
This is an early-stage trial testing a new drug called HH160 in patients with advanced cancer (solid tumors). Researchers want to find the right dose and learn how well it works and what side effects it causes.
Waratah, New South WalesAges 18–75 - NCT06222879RecruitingPhase 1/Phase 2
New drug combinations for advanced breast cancer
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
Changsha, HunanAges 18–75 - NCT06538896RecruitingPhase 2
Tislelizumab and nab-paclitaxel for advanced triple-negative breast cancer with bone spread
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy), as the first treatment for advanced triple-negative breast cancer that has spread to the bones. It aims to see if this combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT07612215RecruitingPhase 1/Phase 2
Elacestrant for Advanced Triple-Positive Breast Cancer
This trial tests a new drug called elacestrant for advanced breast cancer that is triple-positive (positive for three hormone receptors: ER, PR, and HER2). The drug may help slow or shrink cancer that has progressed despite previous treatments.
New York, New YorkAges 18 years+ - NCT07601178RecruitingPhase 2
Immunotherapy and targeted drugs for advanced triple-negative breast cancer
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
Nanjing, JiangsuAges 18–75 - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
New Haven, ConnecticutAges 18 years+ - NCT06636981RecruitingPhase 2
Combination therapy for advanced triple negative breast cancer
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07544056RecruitingPhase 2/Phase 3
BEBT-209 Plus Chemotherapy for Triple-Negative Breast Cancer
This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07551050Recruiting
Sacituzumab Govitecan for Advanced HER2-Negative Breast Cancer
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07540533RecruitingPhase 2
Toripalimab Plus Chemotherapy for Advanced HER2-Negative Breast Cancer
This trial tests a combination of toripalimab (an immunotherapy drug) with chemotherapy to treat advanced breast cancer that is HER2-negative. The goal is to see if this combination can help slow or stop cancer growth in patients who have already tried other treatments.
Zhengzhou, HenanAges 18 years+ - NCT07510802RecruitingPhase 1/Phase 2
CAR-NK cells for advanced HER2+ or triple-negative breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets specific proteins on breast cancer cells. It's for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments or can't take them.
Shenzhen, GuangdongAges 18–75 - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06492005RecruitingPhase 2
Study of 9MW2821 for advanced triple-negative breast cancer
This trial tests a new drug, 9MW2821 (sometimes with a PD-1 inhibitor), for people with advanced triple-negative breast cancer. It may be an option if you've already tried standard treatments or haven't started any yet.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07486089RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for advanced breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
Shenzhen, GuangdongAges 18–75 - NCT06793332RecruitingPhase 2
Ivonescimab and Trodelvy for breast cancer with brain metastases
This trial tests two drugs (Ivonescimab and a Trop2 ADC) for people with triple-negative breast cancer that has spread to the brain. It aims to see if this combination can shrink brain tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06786026RecruitingPhase 2
Drug combo plus chemotherapy for first-line advanced triple-negative breast cancer
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07401537RecruitingPhase 2
Comparing two schedules of immunotherapy for advanced triple-negative breast cancer
This trial tests whether giving immunotherapy less often (extended dose intervals) works as well as the standard schedule for people with advanced triple-negative breast cancer who have already completed 6 cycles of first-line treatment. It aims to see if a longer break between doses can be just as effective with fewer hospital visits.
Guangzhou, GuangdongAges 18–70 - NCT07391956Recruiting
Palliative care for advanced heart failure or cancer
This study tests whether special supportive care (called tiered palliative care) can help people with advanced heart failure or certain advanced cancers feel better and have fewer hospital visits. If you live in Manhattan or Queens, speak English or Spanish, and meet the other requirements, you may be able to join.
Astoria, New YorkAges 18 years+ - NCT07372079RecruitingPhase 2
Immunotherapy and chemotherapy before surgery for early triple-negative breast cancer
This trial tests a new immunotherapy combination with chemotherapy given before breast cancer surgery, to shrink the tumor and improve outcomes. It's for people with early-stage triple-negative breast cancer whose tumors are larger than 2 cm.
TianjinAges 18–75 - NCT06193525RecruitingPhase 2
Talazoparib for advanced breast cancer with a DNA repair defect
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
Leiden, South HollandAges 18 years+ - NCT06851299RecruitingPhase 2
Trop2-ADC alone or with immunotherapy for advanced triple-negative breast cancer
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–70
Hear when a new Advanced Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced triple negative breast cancer?
- Yes. Clin2 currently lists 197 recruiting advanced triple negative breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced triple negative breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced triple negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Triple Negative Breast Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Metastatic Triple-negative Breast Cancer
- HR-positive, HER2-negative Advanced Breast Cancer
- Breast Cancer Triple Negative
- Locally Advanced Triple-Negative Breast Carcinoma
- Triple Negative Breast Cancer (TNBC), Early Setting
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.